Objectives: Therapeutic hypothermia has been of topical interest for many years and with the publication of two international, multicenter randomized controlled trials, the evidence base now needs updating. The aim of this systematic review of randomized controlled trials is to assess the efficacy of therapeutic hypothermia in adult traumatic brain injury focusing on mortality, poor outcomes, and new pneumonia. Data Sources: The following databases were searched from January 1, 2011, to January 26, 2018: Cochrane Central Register of Controlled Trial, MEDLINE, PubMed, and EMBASE. Study Selection: Only foreign articles published in the English language were included. Only articles that were randomized controlled trials investigating adult traumatic brain injury sustained following an acute, closed head injury were included. Two authors independently assessed at each stage. Data Extraction: Quality was assessed using the Cochrane Collaboration's tool for assessing the risk of bias. All extracted data were combined using the Mantel-Haenszel estimator for pooled risk ratio with 95% CIs. p value of less than 0.05 was considered statistically significant. All statistical analyses were conducted using RevMan 5 (Cochrane Collaboration, Version 5.3, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).
T herapeutic hypothermia (TH) is used in the treatment of a variety of conditions from traumatic brain injury (TBI) to unconscious survivors of cardiac arrest (1, 2) . TBI has the potential to be devastating on both a personal and socioeconomic basis. The most recent review assessing the epidemiology of TBI in Europe suggests crude mortality ranges from 3.3 to 28.10 per 100,000 population per year (3) . Although the mortality is similar to an earlier review (4) , there has been a suggested shift in the mechanism of injury from road traffic accidents to falls (3) .
There has been debate on both the overall efficacy and depth of TH required. The 2014 predecessor of this systematic review found some clinical benefit to TH in TBI (5) . However, one of the most recently published international multicentre randomized controlled trials (RCTs) was stopped early due to concerns over patient safety (6) . Similarly an RCT published in 2016 showed that strict fever control was as good as prolonged TH (7) . The most recent systematic reviews have also reported conflicting results (5, 8, 9) . A 2016 meta-analysis was unable to demonstrate improved survival and suggested that TH may increase the risk of new pneumonia and even cardiovascular complications (8) . Conversely, a large meta-analysis reported a benefit of TH, but this may be due to the influence of a large number of observational studies (9) .
The primary aim was to use RCTs to update the evidence base on the use of TH when administered to adult patients in intensive care following TBI. The main outcomes of interest were mortality, poor outcomes, and new pneumonia. Secondary aims were a comparison of control groups, early (< 24 hr from injury) versus late (> 24 hr) TH, and the effect of follow-up durations.
MATERIALS AND METHODS

Search Strategy and Selection Criteria
Searches were not restricted by publication status. Only foreign articles published in the English language were included. The following databases were originally searched from January 1, 2011, to March 31, 2016 
Ethical Approval and Consent
No ethical approval or patient consent was required.
Methodological Criteria for Selection of RCTs
The inclusion criteria were that trials must be 1) RCTs; 2) investigate adult moderate (Glasgow Coma Scale [GCS] score, 9-12) or severe (GCS ≤ 8) TBI; 3) that was sustained following an acute, closed head injury. The use of TH was the intervention of interest. RCTs with no control group were excluded. For the purpose of this review, TH is defined as any intervention with the intention of reducing core body temperature to below the physiologic norm (36°C). Patient outcomes at follow-up were assessed according to mortality and poor outcome data. Participants/Population For inclusion, patients must be adults and have sustained an acute, closed head injury. Adults were defined as being at the legal age for consent in the country the study was conducted in. Trials were excluded if they contained only neonatal or pediatric patients or open head injuries. Only trials meeting all inclusion criteria and no exclusion criteria were included.
Data Extraction
The output of all searches was exported into Microsoft Word 2008 for Mac (Microsoft, Redmond, WA) and assessed by two coauthors. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (10) statement was followed at all three review stages. Defined inclusion and exclusion criteria were used. First, duplicates from across the databases were removed, and then the titles were assessed. Second, abstracts were reviewed. Third, full-text reviews were undertaken, and the final decision on inclusion was made. A third reviewer was available if needed.
Risk of Bias
The Cochrane Collaboration's tool for assessing the risk of bias (11) was used. The following areas were assessed: selection, performance, detection, attrition, and reporting bias; this covered the relevant areas of allocation concealment, blinding, intention-to-treat analysis, and completeness of follow-up. In comparison with the previous review (5), academic bias was also included at this stage. Academic bias was considered to be present if the author had two or more RCTs included in this systematic review. The included RCTs underwent domainbased assessment of risk of bias; this included potential confounding factors. The maximum score available was 18 points with a high score equating to the least risk of bias (Supplemental Table 1 , Supplemental Digital Content 3, http://links.lww. com/CCM/D474; and Supplemental Table 2 , Supplemental Digital Content 4, http://links.lww.com/CCM/D475). A modified Jadad quality score was also analyzed (12) (Supplemental Table 3 , Supplemental Digital Content 5, http://links.lww.com/ CCM/D476). 
Data Synthesis
Review Manager (RevMan, Cochrane Collaboration, Version 5.3) was used for data analysis.
Statistical Analyses
Mortality, poor outcomes, and new pneumonia data were extracted, and the risk ratio (RR) and corresponding 95% CIs were calculated. The Mantel-Haenszel approach was used to assess the significance of the overall RR (RR overall ) as an effect estimate using the null hypothesis RR overall equals to 1 using the z test. As per the Cochrane Handbook, both fixed and random effects were first generated (13) . Statistical heterogeneity was assessed using the chi-square and I 2 index tests to estimate the degree of trial variability. Thresholds for interpretation of I 2 heterogeneity were also taken from the Cochrane Handbook, with 0-40% for possible low heterogeneity, 30-60% for possible moderate heterogeneity, 50-90% for possible substantial heterogeneity, and 75-100% for possible high heterogeneity (14) . When an I 2 value crossed two ranges, then the lower heterogeneity rating was used.
Sensitivity Analysis
Forest plot analyses were preformed for all included RCTs accounting for the risk of bias.
RESULTS
The PRISMA flow diagrams can be seen in Supplemental Diagram 1 (Supplemental Digital Content 6, http://links.lww. com/CCM/D477); originally 1,564 papers were identified with a further 263 papers at the prepublication search. The final analyses included 22 trials (6, 7, ; this includes data for three new trials (6, 7, 32) with one trial being identified during the prepublication search (32) . One trial included in the 2014 review has now published with additional data (7, 35) . These trials enrolled 2,346 patients. Only one trial did not include mortality data (30) . Documents related to the risk of bias domains and quality scoring can be found in Supplemental Table 4 (Supplemental Digital Content 7, http://links.lww.com/CCM/ D478). The primary and secondary aims are addressed below. All primary aim analyses had fixed-and random-effects models generated. There was no difference in statistical significance, so fixed-effects models have been used throughout. Supplemental Table 5 (Supplemental Digital Content 8, http://links.lww.com/ CCM/D479) details the RCT inclusion differences between this systematic review and previous large reviews. The PRISMA flow diagrams can be found in Supplemental Diagram 1 (Supplemental Digital Content 6, http://links.lww.com/CCM/D477), and the characteristics of the included RCTs are shown in Supplemental Table 6 (Supplemental Digital Content 9, http://links. lww.com/CCM/D480).
Risk of Bias and the Quality of Included RCTs
Using the Cochrane Collaboration's tool for assessing the risk of bias, each included RCT was given a score out of 18. Two RCTs scored 14 or more (top quartile) so were considered to have a low risk of bias. Conversely, 20 RCTs scored 13 or less and so were considered to have a high risk of bias (Supplemental Table  1 , Supplemental Digital Content 3, http://links.lww.com/CCM/ D474; and Supplemental Table 2 , Supplemental Digital Content 4, http://links.lww.com/CCM/D475). These scores are used for further analysis of risk of bias for the primary outcomes of mortality, poor outcomes, and new pneumonia.
Primary Aims
Mortality Results. Mortality was reported in 21 studies, totaling 2,330 patients (Fig. 1) . Two studies had a low risk of bias and showed a higher mortality in the TH group (RR, 1.37; 95% CIs, 1.04-1.79; p = 0.02), whereas the 19 studies with high risk of bias showed a higher mortality in the control group (RR, 0.70; 95% CI, 0.60-0.82; p < 0.00001). There was possible high heterogeneity between the two subgroups (I 2 = 94.4%). Poor Outcomes. Twenty-two trials reported on poor outcome, involving 2,346 patients (Fig. 2) . When the two low risk of bias studies were analyzed, they showed that poor outcomes were more likely in the TH group (RR, 1.16; 95% CI, 1.02-1.32; p = 0.03). Conversely, when the 20 studies with a high risk of bias were analyzed together, they showed significantly more poor outcomes in the control group (RR, 0.71; 95% CI, 0.64-0.77; p < 0.00001). There was possible high heterogeneity between the two subgroups (I 2 = 97.3%). New Pneumonia Results. Fourteen studies reported new pneumonia, accounting for 1,188 patients (Fig. 3) . The two low risk of bias studies showed no significant difference in new pneumonia between the two groups (RR, 1.41; 95% CI, 0.72-2.79; p = 0.32). Whereas the 12 high risk of bias studies suggested significantly more new pneumonia in the TH group (RR, 1.51; 95% CI, 1.23-1.86; p = 0.0001). There was possible low heterogeneity between the two subgroups (I 2 = 0%).
Secondary Aims
Mortality: Comparison of Control Groups. The first subanalysis on mortality specifically assessed the methodology used for temperature management in the control groups (Fig. 4) . There was no significant difference in mortality between the TH and control groups with controlled normothermia (RR, 0.85; 95% CI, 0.70-1.03; p = 0.09) (13 studies; 1,157 patients). However, there was significantly greater mortality in the no temperature control group compared with the TH group (RR, 0.81; 95% CI, 0.68-0.97; p = 0.02) (eight studies; 1,173 patients). There was possible low heterogeneity between the two subgroups (I 2 = 0%). 
Mortality: Comparison of Controlled Normothermia Temperature Ranges.
The results for those RCTs that implemented controlled normothermia of any degree were analyzed in isolation (Fig. 5) . The groups were split into those that ensured their controlled groups were less than 38°C (seven studies; 823 patients) and those that included 38°C within their "normothermia" control range (six studies; 334 patients). Those studies that stated controlled normothermia without specific temperature ranges were placed in the latter group. Those studies that controlled to less than 38°C showed no significant difference in mortality outcomes between the control group and TH group (RR, 0.98; 95% CI, 0.77-1.23; p = 0.83). Contrastingly, those control groups that included 38°C within their normothermia range showed significantly more mortality in their control groups (RR, 0.61; 95% CI, 0.44-0.87; p = 0.005). There is possible substantial heterogeneity between the two subgroups (I 2 = 79.2%). Mortality and the Effect of Timings: Early (< 24 hr From Injury) Versus Late (>24 hr) TH. Two groups were created that were divided into those RCTs that implemented early hypothermia (< 24 hr from injury) (16 studies; 1,602 patients) versus late hypothermia (> 24 hr after injury) (four studies; 641 patients) (Supplemental Fig. 1 , Supplemental Digital Content 10, http://links.lww.com/CCM/D481). For those patients with early hypothermia, there was significantly greater mortality in the control group compared with the TH group (RR, 0.74; 95% CI, 0.62-0.87; p = 0.0004). Whereas for those patients with late hypothermia, there was no significant difference in mortality between the control and TH groups (RR, 1.08; 95% CI, 0.86-1.34; p = 0.51). There is possible substantial heterogeneity (I 2 = 85.9%) between the early and late hypothermia subgroups. Mortality and the Effect of Timings: Duration of Follow-Up. Two groups were created that analyzed those RCTs with follow-up for 3 months (five studies; 271 patients) versus those with follow-up for 6+ months (16 studies; 2,059 patients) (Supplemental Fig. 2 , Supplemental Digital Content 11, http://links.lww.com/CCM/D482). For those followed up for 3 months, there was no significant difference in mortality between the control and TH groups (RR, 0.73; 95% CI, 0.46-1.17; p = 0.20). Whereas studies with follow-up for 6+ months showed significantly greater mortality in the control group (RR, 0.84; 95% CI, 0.73-0.96; p = 0.010). There was possible low heterogeneity between the two subgroups (I 2 = 0%).
DISCUSSION
Overall, this review highlights several areas of importance that discredit the use of TH in adult TBI. First, those studies with a high risk of bias are more likely to show that TH improves mortality. As far as, the authors are aware this is the first time that the quality of studies has been statistically shown to impact on the conclusions drawn and may go some way to explain the discrepancies of the most recent reviews. Similarly, the level of subgroup heterogeneity appears important in several of the discussed analyses. Second, this review highlights the importance of avoiding fever in the control groups so as not to overestimate any benefit from using TH. When controlled normothermia is used, then TH is no longer beneficial. Eurotherm3235 used normothermia in their control population and showed harm from TH (6) . Recent guidelines detail the importance of fever avoidance after injury and in the merits of controlled normothermia in cases of refractory fever (36) . Furthermore, the Impact of Fever Prevention in Brain Injured Patients (INTREPID) clinical trial will investigate prophylactic fever prevention versus reactive fever control (37) .
Third, the timing of TH implementation may be important. There is a lower mortality in those who had TH implemented within 24 hours; this could suggest that cooling early is most beneficial or that those patients undergoing late TH may have more severe injuries and compounding factors, such as, difficult to control intracranial pressure. The two recent multicentre RCTs both investigated late TH and both showed harm from TH (6, 7). The ongoing trial Prophylactic Hypothermia Trial to Lessen Traumatic Brain Injury (POLAR-RCT) is a study of early hypothermia for neuroprotection and could provide further evidence to support this hypothesis (38) .
Additionally, studies have provided evidence that TH may be more beneficial in those patients who are cooled after surgical hematoma evacuation as opposed to postdiffuse brain injury; this shows that the underlying pathophysiology may be important in patient selection (39) . Further analysis was not possible in this article as TBI patients are rarely dichotomized into those with focal or diffuse injuries.
There was significant variation in the length of follow-up post injury ranging from 3 months to 4 years. This has also been a factor in other systematic reviews. In the context of hypothermia after cardiac arrest, it has been suggested that 6 months is the earliest time point that neurologic status should be assessed (40, 41) .
This review has several similarities to recent review articles but also some significant differences. Crossley et al (5) were able to demonstrate a significant reduction in mortality and poor outcomes with the use of TH. However, Zhu et al (8) agree with the most recent multicenter RCTs as Eurotherm3235 (6) found evidence of harm from TH whereas the Brain Hypothermia study (B-HYPO) (7) found no improvement in outcomes. Importantly, both recent RCTs avoided fever in their control groups, and this does differ from the control groups of previous RCTs (6, 7).
There are several ongoing RCTs that are yet to publish and may add evidence to our hypotheses. These are INTREPID (37), POLAR-RCT (38) , and the RCT of Long-Term Mild Hypothermia for Severe TBI trial (LTH-I) (42) .
CONCLUSIONS
Overall, this review does not support the use of TH following adult TBI and highlights the importance of fever management in the control group.
